EVALUATION OF RESPONSE TO METHOTREXATE BY A FUNCTIONAL INDEX IN JUVENILE CHRONIC ARTHRITIS

被引：24

作者：

RAVELLI, A ^{[1
]}

VIOLA, S ^{[1
]}

RAMENGHI, B ^{[1
]}

DIFUCCIA, G ^{[1
]}

RUPERTO, N ^{[1
]}

ZONTA, L ^{[1
]}

MARTINI, A ^{[1
]}

机构：

[1] UNIV PAVIA,IRCCS S MATTEO,PEDIAT CLIN,I-27100 PAVIA,ITALY

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷 / 03期

关键词：

JUVENILE CHRONIC ARTHRITIS; METHOTREXATE; FUNCTIONAL CAPACITY; FUNCTIONAL ASSESSMENT;

D O I：

10.1007/BF02208347

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In juvenile chronic arthritis (JCA) the indices of disease activity, such as joint swelling, pain, tenderness, and limitation of motion, may poorly correlate with the degree of functional impairment, Since the improvement of functional capacity is one of the main objectives of treatment, we evaluated the effect of methotrexate (MTX) in 29 children with JCA by assessing both the articular indices and a functional status measure, After 6 months of therapy, 15 of the 29 patients had a significant (greater than or equal to 50%) reduction in the number of joints with active arthritis and/or the articular severity score and were then judged as responders, while 14 did not respond to MTX, In the responder group, the median functional index score decreased from 17 (range: 13-27) at baseline to 13 (range: 13-15) at 6 months (p < 0.001); the median score of the non-responder group was 20 both at baseline and at 6 months (ranges: 14-27, and 13-36, respectively). These results show an improvement of functional impairment in those patients who respond to MTX according to the conventional indices of articular inflammation.

引用

页码：322 / 326

页数：5

共 17 条

[1]

Truckenbrodt H., Hafner R., Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study, Arthritis Rheum, 29, pp. 801-807, (1986)

[2]

Speckmaier M., Findeisen J., Woo P., Et al., Low-dose methotrexate in systemic onset juvenile chronic arthritis, Clin Exp Rheumatol, 7, pp. 647-650, (1989)

[3]

Wallace C.A., Bleyer W.A., Sherry D.D., Salmonson K.L., Wedgwood R.J., Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis, Arthritis Rheum, 32, pp. 677-681, (1989)

[4]

Rose C.D., Singsen B.H., Eichenfield A.H., Goldsmith D.P., Athreya B.H., Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis, J Pediatr, 117, pp. 653-659, (1990)

[5]

Martini A., Ravelli A., Viola S., Burgio G.R., Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis, J Pediatr, 119, pp. 333-334, (1991)

[6]

Halle F., Prieur A.M., Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype, Clin Exp Rheumatol, 9, pp. 297-302, (1991)

[7]

Giannini E.H., Brewer E.J., Kuzmina N., Et al., Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial, N Engl J Med, 326, pp. 1043-1049, (1992)

[8]

Lovell D.J., Newer functional outcome measurements in juvenile rheumatoid arthritis: a progress report, J Rheumatol, 19, pp. 28-31, (1992)

[9]

White P.H., Ansell B.M., Methotrexate for juvenile rheumatoid arthritis, N Engl J Med, 326, pp. 1077-1078, (1992)

[10]

Tugwell P., Bombardier C., Buchanan W.W., Et al., Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires, Arch Intern Med, 150, pp. 59-62, (1990)

← 1 2 →